Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

18 avr. 2023 07h00 HE | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes

CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by SanofiMechanism of Action of Tiziana’s first-in-class, only...
18 juil. 2021 09h30 HE | Source: The Rosen Law Firm PA

FINAL DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action – PRVB

NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2,...
05 juil. 2021 10h08 HE | Source: The Rosen Law Firm PA

ROSEN, A TOP RANKED LAW FIRM, Encourages Provention Bio, Inc. Investors With Losses to Secure Counsel Before Important July 20 Deadline in Securities Class Action – PRVB

NEW YORK, July 05, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2,...
28 mai 2021 15h35 HE | Source: The Rosen Law Firm PA

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors With Losses Over $100K to Secure Counsel Before Important July 20 Deadline – PRVB

NEW YORK, May 28, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...